• Ajoutez une description, des images, des menus et des liens à votre méga-menu

  • Une colonne sans paramètres peut être utilisée comme un espaceur

  • Lien vers vos collections, vos ventes et même des liens externes

  • Ajoutez jusqu'à cinq colonnes

  • Most of us are familiar with plotting an infant's growth against a growth curve. But WHAT is the norm?  And what about growth during fetal development?

    In response to this question, a global team led by Oxford University scientists has developed the INTERGROWTH-21st Project Postnatal Growth Standards (PPGS). This project has created globally validated growth standards for babies based on a study of approximately 60,000 health women from urban areas in eight countries - Brazil, China, India, Italy, Kenya, Oman, the UK, and USA. These standards provide 3rd, 10th, 50th, 90th, and 97th percentile curves for a baby’s growth during pregnancy and for a baby’s size at birth according to gestational age

    These new standards improved upon the ones before them in the sense that they now provide a standard for how babies should grown under normal conditions.  Previously, physicians would compare a newborn’s weight and length against growth charts made from data on previous births in the country they live in, but that method only really works if the population of that country is completely healthy. In other words, if babies born before were unhealthy and the country’s standards are based on a chronically undernourished sample, then newborns are continuously being held to standards based on characteristics of poor health.

    The INTERGROWTH-21st Project addresses this problem by sampling a large pool of healthy women from various countries in order to develop true norms for fetal growth and newborn size that can be used in any country.

    The hope is that these improved guidelines will help doctors identify poor growth in the womb early enough to intervene effectively. Low birth weight is associated with many health problems such as illness and death in infancy and childhood and increased risk of diabetes, high blood pressure, and cardiovascular disease in adulthood. On the other side of the spectrum, being overweight at birth can, too, lead to increased risk to certain diseases later in life and additional burden on the healthcare system.

    In November 2016, the INTERGROWTH-21st team announced its collaboration with the Swiss-based Family Larsson-Rosenquist Foundation. The team hopes that the partnership will help to establish evidence-based feeding and monitoring practices and PPGS for preterm infants, implement feeding protocol and PPGS into selected, influential neonatal units around the world, and to gain high-level health policy support for implementing the feeding protocol and PPGS.

     

    Blog by Vivian Shih



    Laisser un commentaire

    Les commentaires sont approuvés avant leur publication.


    Voir l'article entier

    Medical Devices for Hospitals and NGOs: How to Source the Right products for Maternal and Newborn Care
    Dispositifs médicaux pour les hôpitaux et les ONG : comment acheter les bons produits pour les soins maternels et néonatals

    juin 30, 2026 13 lire la lecture

    Voir l'article entier
    The High Quality Maternova Non-pneumatic anti-shock garment (NASG)
    Le vêtement antichoc non pneumatique (NASG) Maternova de haute qualité

    mai 25, 2026 1 lire la lecture

    Des vêtements antichoc non-pneumatiques (NASG) de haute qualité, conformes à la norme ISO 13485 et marqués CE, produits par Maternova pour être utilisés par les sages-femmes et les obstétriciens du monde entier afin de sauver des vies menacées par l'hémorragie post-partum. Nos NASG respectent les normes les plus strictes et sont approuvés par des centaines de cliniciens.

    Voir l'article entier
    A $.03 pill that could prevent maternal deaths; Part 4
    Une pilule à 0,03 $ qui pourrait prévenir les décès maternels ; 4ème partie

    mai 25, 2026 3 lire la lecture

    L'USPSTF, l'ACOG, la Society for Maternal-Fetal Medicine et la FIGO recommandent toutes l'aspirine à faible dose (LDA) pour les grossesses à haut risque. Les obstacles sont systémiques, comportementaux et structurels.

    Voir l'article entier